Radius Health Inc.—a biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neuroscience, and oncology—has promoted Kim Clarke to general counsel as the company tries to regain its footing after a recent setback.

The Boston-based company in December lost more than half of its stock market value after the transdermal patch version of its approved osteoporosis therapy, TYMLOS, flunked a Phase 3 trial. The company has since enjoyed small wins, including the nonsteroidal oral medicine elacestrant’s passing a Phase 3 study for breast cancer.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]